Mandate

Vinge advises Lantmännen in connection with its divestment of the Gooh ready-to-eat business

Lantmännen Cerealia has signed an agreement to divest its ready-to-eat business under the Gooh brand to Atria Sweden. The deal encompasses the entire business, as well as the Gooh brand. All staff currently working in the business area will be invited to join the transfer. The divestment means that Lantmännen Cerealia is focusing its operations on the grain value chain.

Gooh is a renowned brand with high market shares in a category that has seen an exciting development over the years. The business started on a small scale in the early 2000s, and has since then developed enormously. Today, Gooh serves about 5 million dishes annually through sales outlets throughout Sweden. The range consists of a mix of traditional Swedish home cooking, and flavors from other countries, such as Italian pasta dishes. The range has been developed continuously, but the foundation of chef-prepared meals with carefully selected ingredients remains. Production takes place in a commercial kitchen in Järna in Södermanland, south of Stockholm.

 

The transaction is planned to be carried out through transferring the business to a newly formed company, to which Atria Sweden will acquire all shares. The transaction is subject to regulatory approvals and is expected to be completed later in the spring.

 

Vinge’s team consisted of Christina Kokko, Ulrich Ziche, Carl Sander and Clara Sohlberg (M&A), Johan Cederblad (Environment) and Eva Fredrikson (Commercial Agreements).

 

Read the client’s press release

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026